(Q37974570)

26 August 2017

title

Denosumab in patients with cancer-a surgical strike against the osteoclast (English)

1 reference

26 August 2017

0 references

Janet E Brown

1

1 reference

26 August 2017

Robert E Coleman

series ordinal

2

1 reference

26 August 2017

language of work or name

English

0 references

publication date

10 January 2012

1 reference

Nature Reviews Clinical Oncology

26 August 2017

published in

1 reference

26 August 2017

volume

9

1 reference

26 August 2017

issue

2

1 reference

26 August 2017

page(s)

110-118

1 reference

https://scigraph.springernature.com/pub.10.1038/nrclinonc.2011.197

26 August 2017

exact match

0 references

cites work

Metastasis and bone loss: advancing treatment and prevention.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.197

Examining the metastatic niche: targeting the microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.197

The critical role of the bone microenvironment in cancer metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.197

Understanding and optimizing bone health in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.197

Bisphosphonates in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.197

Osteoclast differentiation and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.197

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.197

Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.197

The RANK/RANKL/OPG triad in cancer-induced bone diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.197

RANK ligand is a prerequisite for cancer-associated osteolytic lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.197

RANK-Fc inhibits malignancy via inhibiting ERK activation and evoking caspase-3-mediated anoikis in human osteosarcoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.197

DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.197

Regulation of cancer cell migration and bone metastasis by RANKL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.197

Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.197

The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.197

RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.197

Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.197

Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.197

Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.197

A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.197

Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo--a role in tumour cell survival?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.197

A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.197

A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.197

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.197

Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.197

Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.197

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.197

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.197

Breast-cancer adjuvant therapy with zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.197

Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.197

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.197

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.197

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.197

Evaluation of coronary artery disease by computed tomography angiography in patients treated for childhood Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.197

An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.197

An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.197

Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.197

Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.197

Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.197

Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.197

Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.197

Mechanisms of bone metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.197

Metastasis to bone: causes, consequences and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.197

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.197

Systemic RANK-Fc protein therapy is efficacious against primary osteosarcoma growth in a murine model via activity against osteoclasts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.197

Markers of bone resorption in patients treated with pamidronate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.197

Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.197

Risk of fracture after androgen deprivation for prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.197

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.197

31 March 2020

Giant cell tumor of bone

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.197

Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.197

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.197

American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22231759

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

New approaches to treating and preventing bone metastases

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22231759

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Skeletal fractures negatively correlate with overall survival in men with prostate cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22231759

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCLINONC.2011.197

1 reference

Dimensions Publication ID

26 August 2017

1049969785

0 references

1 reference